Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) announced on Monday that results from its Phase III trial ESLIM-01 of sovleplenib (HMPL-523) for primary immune thrombocytopenia (ITP) have been published in The Lancet Haematology. Presented at the European Hematology Association 2024 Hybrid Congress on 14 June 2024, the study demonstrated a 48.4% durable response rate with sovleplenib compared to 0% with placebo.

Sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), showed consistent clinical benefits regardless of prior therapies or TPO/TPO-RA exposure. The trial involved 188 adult patients with primary ITP, showcasing a significant improvement in durable response and quality of life, with a median response time of eight days compared to 30 days for placebo.

The study's primary endpoint was met with 48.4% of patients achieving durable responses with sovleplenib, compared to none with placebo (p